The relationships between PON1 activity as well as oxLDL levels and coronary artery lesions in CHD patients with diabetes mellitus or impaired fasting glucose

Coronary Artery Disease

Volumn 19, Issue 8, 2008, Pages 565-573

  Lu, Chengzhi ^a,b   Gao, Yun ^a   Zhou, Hong ^a   Tian, Homing ^a  

^a SICHUAN UNIVERSITY   (China)

^b SHANTOU UNIVERSITY   (China)

Author keywords

Coronary heart disease; Diabetes mellitus; Impaired fasting glucose; Oxidized low density lipoprotein; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GLUCOSE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ANOMALY; CORRELATION ANALYSIS; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; ARYLDIALKYLPHOSPHATASE; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY STENOSIS; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FASTING; FEMALE; HUMANS; HYPERGLYCEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 56849127043     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283109206     Document Type: Article

References (36)

1. Schwenke DC. Metabolic evidence for sequestration of low density lipoprotein in abdominal aorta of normal rabbits. Am J Phys 2000; 279:H1128-H1140.
2. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002; 105:2107-2111.
3. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherogenesis. Nat Med 2002; 8:1218-1226.
4. Mackness MI, Arrol S, Durrington PN. Paranoxonase prevents accumulation of lipoperoxides in low density lipoprotein. FEBS Lett 1991; 286:152-154.
5. Mackness MI, Arrol S, Abbott CA, Durrington PN. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993; 104:129-135.
6. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest 1995; 96:2882-2891.
7. Oranje WA, Rondas-Colbers GJ, Swennen GN, Wolffenbuttel BH. Lipid peroxidation in type 2 diabetes: relationship with macrovascular disease? Neth J Med 1998; 53:61-68.
8. Kopprasch S, Pietzsch J, Kuhlisch E, Graessler J. Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus. J Clin Endocr Metab 2003; 88:1711-1716.
9. Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI. Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci 2000; 98:355-363.
10. Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, et al. Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 1998; 47:598-602.
11. Hanefeld M, Koehler C, Henkel E, Fuecker K, Schaper F, Temelkova-Kurktschiev T. Post-challenge hyperglycemia relates more strongly than fasting hyperglycemia with carotid intima-media thickness: the RIAD study. Diabetic Med 2000; 17:835-840.
12. The expert committee on the diagnosis and classification of diabetes mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-3167.
13. Enbergs A, Dorszewski A, Luft M, Monnig G, Kleemann A, Schulte H, et al. Failure to confirm ferritin and caerulolasmin as risk factors for the extent of coronary arteriosclerosis. Coronary Artery Dis 1998; 9:119-124.
14. Caracciolo EA, Chaitman BR, Forman SA, Stone PH, Bourassa MG, Sopko G, et al. Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients: an ACIP Database Study. Circulation 1996; 93:2097-2105.
15. Caracciolo EA, Davis KB, Sopko G, Kaiser GC, Corley SD, Schaff H, et al. Comparison of surgical and medical group survival in patients with left main equivalent coronary artery disease. Long-term CASS experience. Circulation 1995; 91:2335-2344.
16. Ellis SG, Roubin GS, King SB III, Douglas JS Jr, Weintraub WS, Thomas RG, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988; 77:372-379.
17. Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB III, McCallister BD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993; 88:2987-3007.
18. Valabhji J, McColl AJ, Schachter M, Dhanjil S, Richmond W, Elkeles RS. High-density lipoprotein composition and paraoxonase activity in type 1 diabetes. Clin Sci (Lond) 2001; 101:659-670.
19. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001; 38:163-169.
20. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM, et al. Glycation impairs high density lipoprotein function. Diabetologia 2000; 43:312-320.
21. Mukherjee S. Genetics and molecular biology: rationale for targeting high-density lipoprotein cholesterol for therapeutic intervention. Curr Opin Lipidol 2006; 17:602-605.
22. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radical Bio Med 1999; 26:892-904.
23. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 2002; 277:4301-4308.
24. Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complicat 2002; 16:24-28.
25. Mackness B, Mackness MI, Arrol S, Turkie W, Julier K, Abuasha B, et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. Atherosclerosis 1998; 139:341-349.
26. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscl Throm Vas 2000; 20:2441-2447.
27. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Chris Roberts EH, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscl Throm Vas 2001; 21:1451-1457.
28. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular disease. Arterioscl Throm Vas 2003; 23:1465-1471.
29. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 2003; 107:2775-2779.
30. Granér M, James RW, Kahri J, Nieminen MS, Syvänne M, Taskinen MR. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Coll Cardiol 2006; 47:2429-2435.
31. Toshima S, Hasegawa A, Kurabayashi M, Itabe H, Takano T, Sugano J, et al. Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease. Arterioscl Throm Vas 2000; 20:2243-2247.
32. Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 2001; 103:1955-1960.
33. Tian HM, Liang JZ. The determination of oxLDL and its clinical signification. Chin J Endocrinol Metabol 1992;8:69-71.
34. Shimada K, Mokuno H, Matsunaga E, Miyazaki T, Sumiyoshi K, Kume A, et al. Predictive value of circulating oxidized LDL for cardiac events in type 2 diabetic patients with coronary artery disease. Diabetes Care 2004; 27:843-844.
35. Turk Z, Sesto M, Skodlar J, Ferencak G, Pokupec R, Turk N, et al. Products of advanced glycation in patients with type 2 diabetes and vascular disease. Ann Clin Biochem 2003; 40:552-559.
36. Luoma JS, Kareinen A, Narvanen O, Viitanen L, Laakso M, Yla-Herttuala S. Autoantibodies against oxidized LDL are associated with severe chest pain attacks in patients with coronary heart disease. Free Radical Bio Med 2005; 39:1660-1665.